August Troendle Sells 4,000 Shares of Medpace (NASDAQ:MEDP) Stock

Posted by Geri Gentry on Aug 29th, 2026

Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) CEO August Troendle sold 4,000 shares of the company’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $620.03, for a total transaction of $2,480,120.00. Following the sale, the chief executive officer directly owned 540,544 shares in the company, valued at $335,153,496.32. This trade represents a 0.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Medpace Price Performance

Shares of MEDP stock opened at $600.65 on Friday. The stock has a market cap of $16.76 billion, a P/E ratio of 35.21, a P/E/G ratio of 2.73 and a beta of 1.15. The company has a fifty day moving average price of $565.33 and a two-hundred day moving average price of $494.55. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90.

Medpace (NASDAQ:MEDP – Get Free Report) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period in the previous year, the business earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Johnson Financial Group Inc. bought a new position in Medpace in the 2nd quarter valued at about $27,000. Geneos Wealth Management Inc. lifted its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the last quarter. Elyxium Wealth LLC bought a new stake in shares of Medpace during the fourth quarter worth approximately $30,000. Jones Financial Companies Lllp bought a new stake in shares of Medpace during the second quarter worth approximately $30,000. Finally, Allied Private Wealth LLC acquired a new position in shares of Medpace in the second quarter valued at approximately $31,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analysts Set New Price Targets

MEDP has been the topic of a number of recent analyst reports. Barclays set a $600.00 price target on Medpace in a research report on Thursday, July 23rd. Royal Bank Of Canada raised their price objective on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. BMO Capital Markets boosted their target price on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Finally, Robert W. Baird raised their price target on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and a consensus target price of $584.18.

Read Our Latest Research Report on MEDP

About Medpace

(Get Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.